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Summary 
The high affinity immunoglobulin E receptor (FcelLl) and the B and T  cell antigen receptors 
(TCK)  are multimeric complexes containing subunits with cytoplasmic antigen recognition 
activation motifs (ARAMs). The presence of multiple motifs may be a way to amplify a single 
signal or provide independent activation modules. Here we have compared the signaling capacity 
of the same FceKI 3` motif in the context of two different  receptors,  FceKI and TCK/CD3, 
simultaneously reconstituted on the surface of the same ~'-deficient T cell line. Both reconstituted 
receptors mediate early (phosphorylation) and late (interleukin [IL]-2 release) signals. Mutation 
of the two tyrosine residues of ARAM 3` alters early signaling by both receptors,  but the set 
of substrates phosphorylated via ARAM 3` is different for each receptor and is thus dependent 
on the receptor context. Furthermore, the mutations prevent FceKI- but not TCK/CD3-mediated 
IL-2 release. These data demonstrate that ARAM 3` is necessary for allowing both receptors 
to phosphorylate the complete set of substrates,  and that the CD3 complex, unlike the FceKI 
chain, contains activation modules capable of compensating for the absence of a functional 
ARAM 3' in generating late signals such as IL-2 release. 
T 
he B and T cell antigen receptors (TCR/CD3), the high 
(Fc3,RI) and low (Fc~RIII/CD16) a~nity Fc receptors 
for IgG, and the high affinity Fc receptor for IgE (FceRI) 
belong to a class of multimeric receptors associated with non- 
receptor tyrosine kinases (1-12). The activation of these ki- 
nases is one of the first steps in the signaling cascade, allowing 
the multimeric receptors to initiate various specialized func- 
tions. FceRI is a tetrameric complex formed by an IgE-binding 
c~ chain, a ~ chain, and a homodimer of 3` chains (13, 14). 
The TCR/CD3 complex is also a multichain structure com- 
posed of the two antigen-binding oL and/~ chains, the three 
invariant chains 3`, ~, and E constituting the CD3 complex, 
and one of the six possible dimers formed by disulfide linkage 
between TCR ~', 71, and FceRI 3' chains (15-17). The homo- 
dimers 3`3` and ~'~" and the heterodimer 3`~" are also part of 
one Fc3' receptor (Fc3,RIII/CD16) and are therefore subunits 
common to Fc and T cell receptors (16-25).  The high level 
of homology between the transmembrane domains of 3' and 
~" (26) may explain why these dimers associate equivalently 
with various receptor complexes and appear interchangeable. 
In addition, the presence of these 3/- or ~'-containing dimers 
1 Both authors contributed equally to this work. 
is required for efficient surface expression of the multimeric 
complexes (18, 21-23,  27, 28). 
The cytoplasmic tails of the FceRI 3`, ~', and ~/chains con- 
tain a common 18-amino acid motif named antigen recogni- 
tion activation motif (ARAM)  2 (29-31), which, when fused 
to the extracellular and transmembrane part of an unrelated 
transmembrane protein, confers receptor-like activity to the 
chimeric molecule (32-38). Signaling through this motif is 
absolutely dependent on the presence of two intramotif tyro- 
sines (3'4, 36-38). ARAMs are also present in the 3`, ~, and 
e chains of CD3 and in the fl chain of Fcel~I (29-31).  The 
fact that ARAM ~" or ARAM 3/by itself is able to generate 
the various signals observed with the entire receptor raises 
the question of the function of the other ARAMs present 
in the same receptor.  In the TCR it has been shown that 
two autonomous transduction modules exist: the ~'chain and 
the 3'6e chains (39). A TCR with a truncated ~" chain devoid 
of ARAMs is able to induce IL-2 release via the CD3 com- 
2 Abbreviations used in this FaFer: ARAM, antigen recognition activation 
motif; CTLL, cytotoxic T  lymphocyte leukemia;  DNP, dinitrophenyl; 
FBS, fetal bovine serum; HSA, human serum albumin; NEPHGE, non- 
equilibrium pH gd dectrophoresis. 
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Ig'B also control distinct signals  (4).  Similarly,  the ~  and 
3' chains of FceRI control different tyrosine kinases: fl binds 
Lyn of the Src family  and 3' activates Syk of the Syk/ZAP-70 
family (40). 
The FceRI 3, chains are part of at least four different types 
of receptors:  FcyRI (41, 42),  Fc3'RIII (18, 21, 22),  FceRI 
(13, 14), and TCR (17). Some of these 3' chain-containing 
receptors  are expressed concomitantly on the surface of the 
same cell. For example, FceRI and Fc3,RIII are both expressed 
on mast cells, and Fc3'RIII and TCR are expressed on sub- 
sets ofT cells. Therefore we wanted to address whether FceRI 
% and the FceRI 3, motif  in particular, could function differ- 
ently when part of different multimeric complexes. We have 
reconstituted two different 3' chain-containing complexes, 
FceRI and TCR, on the surface of the same cell, and have 
compared the signaling capacity of each 3' chain motif in the 
natural environment of their respective receptor. To avoid any 
interference from endogenous subunits, we have chosen to 
reconstitute these receptors in a T cell line deficient in ~', % 
and ~/chains (28). 
Materials  and Methods 
Cell Lines and Media.  2.M2 cells, a variant of the 2B4 mouse 
T cell line that lacks the ~"  chain of the TCK (28) (kindly provided 
by R. Klausner, National Institutes of Health, Bethesda, MD), 
were cultured in RPMI-1640 with 10% (vol/vol) heat-inactivated 
fetal bovine serum (FBS), 50 #M B-ME and 2 mM t-glutamine. 
An Ib2-dependent T cell, CTLL (a gift of H. Rigger, National 
Cancer Institute, National Institutes of Health, Frederick, MD), 
was maintained in RPMI-1640 with 10% FCS, 2 mM t-glutamine, 
and 20 U/ml rhlL-2. The BW# ceils were previously  described (39). 
Reagents and Antibodies.  Dinitrophenyl (30) human serum al- 
bumin (DNP-HSA, 30 molecules of DNP per molecule of HSA) 
was from Sigma Chemical Co. (St. Louis, MO). Radiochemicals 
were purchased from Amersham Corp. (Arlington Heights, IL). 
The chemiluminescent substrate for Western blotting, AMPPD, 
was purchased from Tropix, Inc. (Bedford, MA). 
Anti-DNP monoclonal mouse lgE was purified from the super- 
natant of hybridoma Hi-DNP e 26.82 grown in a Miniflo-path 
bioreactor (Amicon,  Beverly,  MA) by ion e~change  chromatography 
on diethylaminoethyl-Trisacryl  (IBF Biotechnics,  Columbia, MD). 
The goat anti-hamster  IgG and the goat anti-mouse IgG were 
purchased from Organon  Teknika (Durham,  NC).  Fluorescein- 
conjugated rabbit anti-hamster lgG was from Pierce Chemical Co. 
(Rockford, IL). The goat anti-mouse and goat anti-rabbit  anti- 
bodies conjugated to alkaline phosphatase were from Jackson Im- 
munoResearch Labs, Inc. (West Grove, PA); the antiphosphotyro- 
sine antibody  4G10 was from UBI (Lake  Placid, NY); the anti-FceRI 
subunit antibody JRK and the anti-FceRI 3, subunit antiserum 
were described previously (43). 
12sI-iodination of BC4, an anti-rat FceRI ~ monoclonal anti- 
body (kind gift of  Reuben Siraganian, National Institute of  Dental 
Research, National Institutes of Health) and 2Cll, a monoclonal 
anti-CD3e (kind gift of  Jeffrey Bluestone, University of Chicago, 
Chicago, IL) was performed by use of chloramine T. 
Mutants and Tmnsfectians.  Point  mutations in rat Fc~RI  3" cDNA 
were created via PCR. The full-length eDNA was amplified  with 
a 5' primer (bp 16-37) including the first ATG and a 3' primer 
(bp 289-172) starting after the stop codon, converting tyrosine (Y) 
residues to phenylalanine  (F). 2.M2 cells  were cotransfected  by elec- 
troporation with rat FceRI ot and/3 cDNAs subcloned in pcDL- 
SRc~ 296 (44) and with either the wild-type or the mutated form 
of  rat 3, cDNA subdoned in pBJlneo (45). Cells were grown under 
G418 (GIBCO BRL, Gaithersburg, MD) selection, and resistant 
clones were selected for FceRI and CD3 surface expression. BW8 
cells were transfected  with either the wild-type or the mutated form 
of rat 3, cDNA subcloned in pBJlneo. 
Flow Cytometry Analysis.  Flow cytometric analysis was per- 
formed by use of a FACScan  |  (Becton Dickinson & Co., San Jose, 
CA) after staining of the 2.M2 cells (5  x  10  s) with 10/~g/ml of 
FITC-conjugated  mouse IgE or 10/~g/ml of  monoclonal  anti-CD3e 
(2Cll) followed  by FITC-conjugated rabbit anti-hamster antibody 
(Organon Teknika). For FcERI, the background staining was as- 
sessed by preincubation with 200/~g/ml of mouse IgE and for 
CD3/TCR by staining with the second antibody only. 
In Vivo Phosphorylation,  Immunoprecipitation, Two-dimensional  Non- 
equilibrium pH Gel Electrophoresis (NEPHGE)-PAGE,  SDS-PAGE, 
and Western Blotting.  2.M2  cells were incubated in phosphate-free 
medium for 4 h at 37~  and then labeled at 3 x  107 cells/ml with 
37 MBq/ml [32p]orthophosphate for 2 h at 37~  The cells (2  x 
107/ml) were incubated at 4~  for 30 rain with 10 #g/ml of anti- 
FceRI c~ (BC4) or anti-CD3e (2Cll) monoclonal antibodies, and 
then stimulated for 2 min with medium alone or with 50/~g/ml 
of the appropriate second antibody, as indicated for individual ex- 
periments. The cells were then immediately washed and lysed as 
previously described (43). The  postnuclear  supernatants were 
precleared with protein A-Sepharose beads, and then immunopre- 
cipitated with antiphosphotyrosine monoclonal antibody bound 
to protein A-Sepharose. For two-dimensional  analysis,  the tyrosine- 
phosphorylated  proteins were loaded at the anode end of  6% acryl- 
amide, 2% amphotine (pH 3.5-10) tube gels. Separation was per- 
formed for 6 h at 500 V. NEPHGE gels were equilibrated for 1 h 
with lx SDS sample buffer and then frozen at -70~  or applied 
directly on top of the second-dimension  gels, which were run at 
20 mA/gel. To show the tyrosine phosphorylation of the 3' chains, 
the proteins precipitated by antiphosphotyrosine antibody were 
eluted with phenylphosphate  and the 3' chains immunoprecipitated 
with anti-3, antiserum. The samples were analyzed by SDS-PAGE 
(13.5% gel under reducing conditions) and autoradiography. 
For Western blotting, 108 cells were lysed in a buffer containing 
1% digitonin, 150 mM NaC1, 50 mM Hepes, pH 7.5, and pro- 
tease and phosphatase inhibitors as previously described (43). The 
postnuclear supernatants were immunoprecipitated and analyzed 
by SDS-PAGE as above, and the proteins were transferred  electropho- 
retically to membranes (Immobilon-P; Millipore Corp., Bedford, 
MA) for 6 h at 50 V. Membranes were then incubated overnight 
in TBS (20 mM Tris, pH 7.5, 500 mM NaC1) containing 5% BSA 
before a 2-h incubation in the same buffer containing 1:200 dilu- 
tion of anti-'), serum. After two washes in TTBS (TBS containing 
0.1% Triton X-100 and 2.5% BSA), the membranes were incubated 
with 0.2 #g/ml goat anti-rabbit antibody conjugated to alkaline 
phosphatase and developed with the chemiluminescence  substrate 
AMPPD according to the manufacturer. 
11_,2  Production and Biological  Assay.  For stimulation with 2Cll, 
flat-bottom 96-well microtiter plates (Costar Corp., Cambridge, 
MA) were coated with 50/zl of PBS containing 10/~g/ml of 2Cll 
(0.5/zg/well).  For stimulation with BC4, microtiter wells were 
first precoated overnight  at  4~  with  2.5  /~g/well of goat 
anti-mouse and then, after  a 2-h saturation  with 10% FBS in RPMI- 
1640, with 1/~g/well of BC4. After 2 h at room temperature and 
1 h at 4~  the wells were washed three times with PBS, and 10  s 
cells in 250/zl of RPMI were added to each well. In all assays, 
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II~2 content by measuring the proliferation of Ib2-dependent mu- 
rine T  cells (CTLL). CTLL cells were incubated with IL2-ffee 
medium for 3 h at 37~  and then extensively washed with the 
same medium; 50-#1 aliquots (3  x  10  s cells/ml)  were plated in 
96-well microtiter plates with serial dilutions of  supernatants. After 
18 h at 37~  1 #Ci of [3H]thymidine  was added to each well for 
6 h. [3H]Thymidine incorporation was quantitated by harvesting 
onto glass fiber filters by use ofa semiantomated cell harvester (LKB 
Wallac, Gaithersburg, MD) and by phdng the filters in a scintilla- 
tion  counter  (Beta  plate  TM  liquid  scintillation  counter;  LKB 
Wallac) (NIH laboratory)  or by direct 13 counting by use of gas 
ionization (Matrix 96 direct beta counter; Packard Instrument Co., 
Meriden,  CT)  (INSERM  laboratory)  (39).  The  two  different 
methods of quantitation explain the differences in the overall 3H 
counts observed with 2.M2 transfectants (NIH laboratory) and BW8 
transfectants (INSERM laboratory). 
Results 
Simultaneous  Expression of  FceRI and TCR/CD3 Complexes 
Containing Wild-type and Mutated 7  Chain Motifs on 2.M2 
Cells.  The cDNAs coding for FceRI o~, fl,  and 3` chains 
were cotransfected into 2.M2 cells, a variant of the 2134 mouse 
T  cell line which lacks TCK ~', TCK ,1, and FceKI 3' and, 
as a result, does not express TCK/CD3 complexes at the cell 
surface (28).  To identify 3, motif-controlled functions, we 
mutated the two intramotif tyrosines, which are required for 
activity (37,  38), and we cotransfected the FceRI 3' mutant 
cDNA with FceRI ot and fl cDNAs (Fig. 1 A). Cotransfec- 
tion  of FceKI oe and fl cDNAs  with  either wild-type or 
tyrosine-mutated 3' cDNA results in cell surface expression 
of FceRI receptors  capable of binding IgE (Fig.  1 B,  left). 
Because the FceRI 3' chain can substitute for the absent TCR 
~"  chain (27), the cotransfected cells also express surface TCK/ 
CD3 complexes (Fig. 1 B, right). Two clones with wild-type 
3` (WT23 and WT66) and three clones with tyrosine-mutated 
3`  (Y1,  YS,  and Yc)  were used for further analysis. 
The levels of the two reconstituted complexes containing 
wild-type 3` chains o~a clone WT23 are approximately equiva- 
lent, as shown by a binding assay using iodinated monodonal 
Figure  1.  Simultaneous  expression of FceKI and TCK/CD3 complexes  containing wild-type or mutated 3` chain. (A) Schematic  representation  of 
the wild-type and tyrosine.mutated FceRI 3/chain. The sequence of ARAM (29) is indicated in bold. The two tyrosine residues that were replaced 
with phenylahnine are indicated by F and their respective amino acid numbers (and single-letter  code of the amino acid that was substituted). (B) 
Flow cytometry analysis  of FceRI and TCK/CD3 surface  expression  in transfected  2.M2 cells. Solid  lines indicate  specific  staining;  dotted lines indicate 
background staining. Untransfected  cells (C); cells cotramfected  with FceKI r~,/3 and either the wild-type 3' (WT) or the tyrosine-mutated  3' (Y) 
cDNAs. (C) Average  antibody-binding  site numbers were calcuhted  from saturation  binding data of mI-hbeled BC4 and 12sI-hbeled  2Cll. Depending 
on the stoichiometry of binding of BC4 to FceRI o~ and 2Cll to TCR e, the receptor numbers are either the ones reported in the table or twice 
as high. (D) Anti-'), immunoblotting of FceRI complexes immunoprecipitated  from total extract with the BC4 monoclonal  antibody and TCR/CD3 
complexes immunoprecipitated  with the 2Cll monoclonal antibody. Mr calibration is shown on the left. 
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(Fig.  1 C)  or by FACS analysis (data  not shown). 
To demonstrate that both FcdLI and TCR/CD3 complexes 
contain FceRI ~/chains, total cell extracts  from WT or Y 
transfectants  were incubated with BC4 and 2Cll. The im- 
munoprecipitates  were then analyzed by SDS-PAGE followed 
by immunoblotting  with anti-y or anti-~. The FceRI com- 
plexes in both transfectants  contain equivalent amounts of 
3, (Fig. 1/3) and B subunits (data not shown). Similarly, anti-3, 
immunoblotting of the anti-CD3e precipitates  shows that 
the TCR/CD3 complexes associate equivalently with wild- 
type and tyrosine-mutated 3' chains (Fig. 1 D). As expected, 
an anti-FceRI B immunoblot and an anti-TCR ~" immuno- 
blot of the anti-CD3e precipitates did not detect any reactive 
bands (data  not shown). 
Engagement of TCR/CD3 and FceRI Induces Tyrosine  Phos- 
phorylation of the "f Chain.  To determine whether stimula- 
tion through reconstituted receptors activates early signaling 
events, we first studied whether cross-linking could induce 
the tyrosine phosphorylation of y. After in vivo labeling of 
the transfected 2.M2 cells with [32P]orthophosphate,  FcdLI 
or TCR/CD3 complexes were engaged (or not) with rele- 
vant mAbs and then cross-linked  with second antibodies. Phos- 
phorylated proteins were eluted from an antiphosphotyro- 
sine immunoprecipitate and reprecipitated with an anti-y 
antiserum before SDS-PAGE (Fig. 2). Phosphorylation  of both 
B and wild-type 3' chains occurred in activated FceRI (lane 
2), as previously described in a mast cell line (43). The wild- 
type 3' chain is also phosphorylated after TCR/CD3 engage- 
ment (lane 4). As expected, the phosphorylation of 3, is lost 
in both receptors when the tyrosines of ARAM-3, are mu- 
tated (lanes 6 and 8).  Thus, each receptor complex is able 
to activate a tyrosine kinase capable of phosphorylating the 
"y chain. In addition, the fact that the mutation of the 3' chain 
does not affect the phosphorylation of the FceRI B chain 
(compare the 35-kD band in lanes 2  and 6) indicates  that 
the kinase responsible  for ~  phosphorylation is not under 
the control of ARAM-% This kinase is likely to be the Src 
family kinase Fyn because in vitro kinase assays after immu- 
noprecipitation with anti-Fyn show an increase in kinase ac- 
tivity after aggregation of either FceRI or TCR/CD3 (data 
not shown). 
The T Motif  Associated with TCR/CD3 and FceRI Controls 
the Phosphorylation of  Different Substrates in 2.M2,  To further 
our understanding of the role of the ~/motif  in the activation 
of tyrosine kinases, we analyzed the tyrosine phosphoryla- 
tion of the various  substrates  induced by the two receptor 
complexes. After engagement of FcdLI or TCR/CD3 com- 
plexes, the 32p-labeled phosphorylated proteins were immu- 
noprecipitated with antiphosphotyrosine antibody and resolved 
Figure 2.  Activation-induced phosphorylation  of 
3/  chains  from  TCR/CD3  and FceRI.  32P-labeled 
wild-type ~/(WT) and tyrosine-mutated y (Y) trans- 
fectants were incubated at 4~  for 30 min with BC4 
or 2Cll, and then stimulated for 2 min with medium 
alone or the specific  second antibody, as indicated for 
individual lanes. The tyrosine-phosphorylated  proteins 
were immunoprecipitated  with antiphospbotyrosine 
antibody, eluted with phenylphosphate  and the "y chains 
immunoprecipitated with anti-'y antiserum, and sepa- 
rated by SDS-PAGE  and autoradiography  as before (43). 
The positions of molecular weight standards and the 
and 3' chains of FcelLI are indicated. 
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and the second SDS-PAGE (Fig. 3). Under resting conditions, 
a number of substrates are phosphorylated (A). At least two 
prominent (a,b) and a few fainter substrates disappear when 
the tyrosines of 3" are mutated (compare A  and C). This in- 
dicates that  the 3' motif directly or indirectly controls  the 
resting level of phosphorylation of these substrates. Engage- 
ment of wild-type FceRI with anti-FceRI ot cross-linked with 
a second antibody (/3) or with IgE and multivalent antigen 
(not shown) increases the phosphorylation of several substrates 
and results in the appearance of an acidic 42-kD phosphorylated 
species  (d)  and  another  around  150  kD  (c). Other  phos- 
phorylated species, although faint, are also reproducibly seen 
around 32, 40 and 48 kD, which correspond to the positions 
of phosphorylated and l~hosphorylated/ubiquitinated  FceRI 
3 chains, already described (46). Among these substrates only 
phosphorylated  after FceRI engagement,  substrate d is the 
only one to disappear  after mutation  of the tyrosines in 3' 
(compare B and D). Therefore activation through the 3" motif 
in the context of Fc6RI controls the phosphorylation of sub- 
strate d. 
Engagement of wild-type CD3 also results in the tyrosine 
phosphorylation of various substrates (Fig. 3, E and F). Most 
of these substrates are common to both CD3 and FceRI en- 
gagement  (compare B and F).  However, at least three sub- 
strates  around  120  kD  (e),  60 kD  ~  and  140  kD  (g)  are 
reproducibly seen only after CD3 stimulation. Moreover, phos- 
phorylation of these three substrates is completely abolished 
when  the  tyrosines of 3'  are mutated  (compare F  and H). 
Therefore, the 3' motif in the context of TCR/CD3 controls 
the phosphorylation of these three substrates. The 42-kD acidic 
substrate d is also phosphorylated by the CD3 pathway, but 
its phosphorylation is not affected by tyrosine mutation  of 
3' and is therefore not under the control of the 3' motif in 
the context of TCR/CD3.  Thus, the 3' motif in the context 
of the two receptors controls the phosphorylation of different 
substrates. 
The 9/Motif Associated With Fc6RI but Not TCR/CD3 Is 
Necessary to Mediate the Release of  lL-2.  We next investigated 
whether the 3' motif plays a role in a later activation event, 
the production of IL-2. Cross-linking of CD3 in both 2.M2 
WT and Y transfectants induces IL-2 production. Two WT 
clones and 3 Y clones were analyzed two to three times each. 
Clone WT66 was always a higher producer than any other 
clone (Fig.  4 A).  This was not due to a higher  level of ex- 
pression of TCR/CD3,  since these levels, which were tested 
by FACS before each experiment, were found comparable (Fig. 
1 B and data not shown).  Those results seem to indicate a 
slightly higher production  of IL-2 by WT compared with 
Y,  with  a marked  heterogeneity between clones. 
The same experiments were performed with the BW~5  trans- 
fectants.  Three WT clones and 3 Y-mutated clones were ana- 
lyzed for IL-2 production after TCR engagement. Comparable 
levels of IL-2 were induced in the different clones (Fig. 4 B). 
Figure  3.  The 3' motif in association with TCR/CD3 and FceRI mediates the phosphorylation of distinct substrates. 32p-Labeled  cells (10  s) were 
stimulated as in Fig. 2 in the absence  (A, C, E, and G) or presence  (B, D, F, and/-/) of the first specific  antibody  and in both cases  with the corresponding 
second antibody. Lysates  were  immunoprecipitated  with the antiphosphotyrosine  antibody  and resolved  by NEPHGE-PAGE  (10% slab  gels) as described 
(46). Mr calibration is shown on the left. WT, wild-type 3';  Y, tyrosine-mutated 3'. 
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Statistical calculations applied to similar experiments confirmed 
that no significant difference was present between the wild- 
type and tyrosine-mutated clones. 
To test the significance of the heterogeneity in the response 
of WT and Y  in 2.M2,  which was not observed in BW& 
we applied the same statistical calculations to the results from 
2.M2. When the comparison was performed between clones, 
that is, the various results from one clone obtained in various 
experiments were combined, there was no significant differ- 
ence between WT  and Y.  We therefore conclude that the 
production of IL-2 after CD3 engagement does not require 
the integrity  of the 3' motif. 
When FceRI was engaged with multivalent  antigen  or 
with BC4 alone, no IL-2 secretion was observed (data not 
Figure  4.  Distinct roles of the 3, motffin mediating II,2 release in the 
context of TCR/CD3 or FceRI. 2.M2 (,4) and BW~ (/3) wild-type (WT) 
and tyrosine~mutated 3' (Y) transfectants were incubated without any 
stimulus or in wells precoated with 2Cll (0.5/zg/wen). (C) 2.M2 WT 
and Y  transfectants were incubated without any stimulus or in wells 
precoated with a goat  anti-mouse antibody (2.5/zg/weU) and BC4  (1 
/zg/well). After 24 h, culture supernatants were harvested and assayed for 
IL-2 content by measuring proliferation of CTLL cells after [3H]thymi- 
dine uptake. 
shown). However, reproducible IL-2 release was induced after 
FcERI engagement with high doses of BC4 bound to a cross- 
linking  specific  antibody  coated  to the 96-well  plates  (see 
Materials  and Methods) (Fig. 4 C). The IL-2 secretion was 
completely abolished when the tyrosines of 3' were mutated. 
Therefore, in the context of FceRI complexes,  the presence 
of the 3, motif was necessary for initiating the signal cascade 
leading  to IL-2 production. 
Discussion 
In this study,  we have cotransfected a ]'-deficient  T  cell 
line with FceRI a, 13, and 3' cDNAs to induce the surface 
expression of two different  FceRI "),-containing receptors, 
252  Roles  of FceRI 3, and Receptor Context FceRI and TCR/CD3. The use of a wild-type FceRI "), chain 
and a mutated form, in which ARAM-3" had been inacti- 
vated by mutating its tyrosine residues to phenylalanine, has 
allowed us to specifically  study the function of ARAM-3' 
in the context of the two different receptors. Both recon- 
stituted TCR/CD3 and FceRI with the wild-type FceRI 3' 
chain are functional, as shown by their capacity to induce 
IL-2 release  and to activate kinase(s). 
The reconstituted FceRI with a tyrosine-mutated FceRI 3' 
loses its capacity to induce IL-2 release even though the 3 
chain is phosphorylated and ubiquitinated upon triggering. 
Like the FceRI 3' chain, the 3  chain contains an ARAM in 
its COOH-terminal cytoplasmic tail. We have recently demon- 
strated that the FceRI 3' chain activates the kinase Syk, while 
3 binds the Src family tyrosine kinase Lyn and controls receptor 
phosphorylation. This led us to propose a model in which 
the full signaling capacity of FceRI is achieved by coopera- 
tion between 3 and 3'. This model is supported by the results 
presented here. When the tyrosines of ARAM-3' are mu- 
tated, the 3 chain cannot initiate the full signaling repertoire 
of the entire receptor. However, by itself it can activate a tyro- 
sine kinase, presumably the Src family kinase Fyn, respon- 
sible for the phosphorylation of  3 and other substrates.  Taken 
together, the results presented here suggest a new classification 
for ARAMs: those able to Control late signals, like the ones 
in CD3, TCR ~', and FceRI 3", and those that do not, like 
the one in FceRI 3. This distinction should help in deter- 
mining how ARAMs control the various arms of the sig- 
naling machinery. 
In contrast with FceRI, the TCR/CD3 complex with a 
tyrosine-mutated FceRI "y is still able to induce IL-2 release 
upon aggregation. Therefore, the other ARAM-containing 
subunits of CD3 are capable of inducing IL-2 release indepen- 
dently. This could also explain the fact that one phosphorylated 
substrate, substrate d in Fig. 3, requires an intact ARAM-3' 
when FceRI is activated but not when TCR/CD3  is acti- 
vated. An alternative module in TCR/CD3 could substitute 
for the mutated ARAM-3" and promote the phosphoryla- 
tion of substrate d. These results are in agreement with the 
findings that both CD3 e and ~" are capable of autonomously 
activating cells (39), and that a TCR/CD3 complex can still 
induce IL-2 production despite the truncation of the cyto- 
plasmic tail of ~" (36). These previous reports have led to the 
concept of two parallel transducing units in the TCR/CD3 
complex, the TCR ~'on the one hand and the CD3 complex 
on the other hand (39).  In this scenario, when FceRI 3' is 
mutated,  the CD3  complex, in particular CD3  ~,  would 
simply take over. 
While the concept of two parallel  transducing units in 
TCR/CD3 seems reasonable to explain the results discussed 
above, it does not satisfactorily explain some other results. 
At least  three substrates,  which are phosphorylated exclu- 
sively after TCR/CD3  engagement, disappear after muta- 
tion of FceRI 3' (Fig.  3). Therefore, CD3 e is not capable 
of repladng FceRI 3' to mediate the phosphorylation of these 
substrates.  The presence of FceRI 3' seems necessary. How- 
ever, FceRI 3' does not mediate the phosphorylation of these 
three substrates after FceRI triggering. Therefore, FceRI 3' 
mediates the phosphorylation of these substrates,  but only 
in the context of the TCR/CD3 complex. We propose that 
the environment of the FceRI 3' motif influences its capacity 
to mediate phosphorylation of various substrates.  If one as- 
sumes that a substrate must associate, even temporarily, with 
the receptor complexes before phosphorylation, then the differ- 
ence in substrates could be due to differences in recruitment 
by the two phosphorylated receptors. This, in turn, could 
be explained by the difference in subunit composition of the 
two receptors. Regardless of the mechanism that might ex- 
plain the differences in substrate phosphorylation, our results 
clearly  demonstrate  that  two  different  receptors  with  a 
common FceRI 3' ARAM expressed on the same cells can 
signal differently. 
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